Cellestis Shareholders OK Acquisition by Qiagen

Shareholders overwhelmingly approved an amended proposal that will result in Qiagen paying around $374 million to acquire the Australian firm.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories